WASHINGTON – Caloric restriction, whether through diet, bariatric surgery, or new sodium-glucose cotransporter-2 inhibitor (SGLT2) medications, could help improve measures of kidney disease in obese patients, according to a Kidney Week 2019 presentation.
As people gain weight, their metabolic rate increases, said Holly J. Kramer, MD, MPH, a professor of public health sciences and medicine in the Division of Nephrology and Hypertension at Loyola University in Chicago, during a talk on the direct and indirect effects of adiposity on the kidney. The kidneys then have to do more, and meet the increased demands by increasing the glomerular diameter so it hypertrophies, yielding an increase in glomerular filtration rate and an increase in renal plasma flow.
WASHINGTON, DC – Children with chronic kidney disease (CKD) have structural changes in the brain associated with poorer intelligence, executive function and academic achievement, compared to healthy children without the disease, according to new research from the University of Iowa presented at Kidney Week 2019 in a session entitled, “Pediatric CKD Is Associated with Abnormal White Matter Integrity”.
An exciting, and sometimes heated, panel and audience discussion occurred today at Kidney Week 2019 on the subject of disruptors in the nephrology market. Major new healthcare players are entering kidney care, bringing perspectives and expertise on technology, big data, and artificial intelligence and integrated payer-provider platforms. These innovators are working to transform the landscape in kidney care. The audience was standing room only and the hour-long question period had a line the entire time.
WASHINGTON, DC -- Biopsies remain the gold standard for diagnosing post-transplant kidney disease but they are imperfect, a speaker said here during Kidney Week 2019. Emerging biomarkers may provide a complement to helping nephrologists diagnose and manage disease. The session entitled, "Needle Phobia: Kidney Transplant Biopsy Alternatives", included four speakers on the topic.
CKD burden continue to remain high in the United States and Medicare spending for all beneficiaries who had CKD exceeded $79 billion in 2016. The 2019 Chronic Kidney Disease issue of NephSAP guides readers through the latest advances in clinical research for this common and costly disease. This issue of NephSAP provides a background of the clinical research published during the years 2017 and 2018, and covers several major areas of CKD research: epidemiology, biomarkers relevant to incidence and progression, genetic variants, cardiovascular disease, weight loss interventions, and novel tools to improve CKD care measures. There have been exciting developments in our understanding of the pathogenesis and treatment options for diabetic kidney disease in the recent years. Several relevant clinical trials that demonstrated improvements in outcomes for those with diabetic kidney disease have been highlighted in this issue. Along with it, several novel risk factors for progression of kidney disease have also been discussed. Cardiovascular disease remains the principal cause of death for adults with CKD. This NephSAP outlines advances in management of atrial fibrillation and the use of device therapy in CKD. The epidemiology and conseqeuences of pulmonary hypertension, peripheral artery disease and congnitive function in those with CKD are also discussed. Clinical practitioners will also be provided with insight into topics ranging from management of obesity along with understanding about novel methodology and tools that have been tested to help improve CKD care delivery. Finally, readers can also test their knowledge with a series of 30 questions.